(Q44552912)

4 December 2017

0 references

Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets (English)

1 reference

4 December 2017

1 reference

2

1 reference

4 December 2017

William C S Cho

1

1 reference

PubMed ID

23259420

4 December 2017

language of work or name

1 reference

1 January 2013

1 reference

Expert Review of Anticancer Therapy

4 December 2017

1 reference

4 December 2017

13

1 reference

4 December 2017

1

1 reference

4 December 2017

5-8

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

4 December 2017

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Complete genome sequencing and network modeling to overcome trastuzumab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Next-generation sequencing and epigenome technologies: potential medical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Sequence analysis of mutations and translocations across breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Differential network biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Leveraging models of cell regulation and GWAS data in integrative network-based association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Disrupting the networks of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Network medicine: a network-based approach to human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Ten years of pathway analysis: current approaches and outstanding challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Genomics: ENCODE explained

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

Architecture of the human regulatory network derived from ENCODE data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.152

21 January 2018

Identifiers

DOI

10.1586/ERA.12.152

1 reference

4 December 2017

1 reference

PubMed ID

23259420